TerrAscend Stock (CSE: TER) (OTCQX: TRSSF) - Investor Dashboard

Summary

Financials (06/30/19)

Capital Structure (08/22/18)

Company Brief

TerrAscend provides quality products, brands, and services to the global cannabinoid market. As the first North American Operator (NAO), with scale operations in both Canada and the US, the Company participates in the medical and legal adult use market across Canada and in several US states where cannabis has been legalized for therapeutic or adult use. Additionally, TerrAscend will soon be the first and only cannabis company with sales in Europe as well as the US and Canada as it has received EU GMP certification for its manufacturing facility in Mississauga, Ontario.

TerrAscend operates a number of synergistic businesses, including Arise Bioscience Inc., a manufacturer and distributor of hemp-derived products; Ascendant Laboratories Inc., a biotechnology and licensing company committed to the continuous improvement of cannabinoid expressing plants; and Solace RX Inc., a proposed Drug Preparation Premises (DPP) focused on the development of novel formulations and delivery forms.

A Strong Growth Platform

April 25, 2019 Investor Day Webcast

Highlights

• Canadian LP with global distribution and multi-state operator in the U.S.
• Strategic investors include Canopy Growth, Canopy Rivers, and JW Asset management
• Licensed producer with significant processing, formulation and manufacturing capabilities
• Management comprised of leaders from healthcare, pharmaceutical, banking and cannabis industries
• Strong pharmaceutical and distribution expertise
• 67,000 sq. ft. facility in Greater Toronto Area, nearby Pearson International Airport
• Brand portfolio including premium cannabis Haven St. , Valhalla premium edibles, Funky Farms CBD extracts, and Original Hemp

Growth Strategy

• Focus on developing protectable intellectual property assets
• Creating quality brands that resonate with patients and consumers
• Ensure the highest standard of ethics and corporate responsibility
• Invest in business streams that will utilize cannabinoids
• Medical cannabis agreement with MCI Medical Clinics, which offers access to more than 1 million patients in Canada
• Acquired U.S. hemp products company Grander Distribution and hemp-derived product developer Arise Bioscience
• Multi-state operator in the United States with plans for growth
• Asset acquisition strategy includes The Apothecarium, which includes cultivation facilities, processing, and dispensaries in California and Nevada

Differentiators

• Pursuing U.S. cannabis markets; one of six new entities granted a vertically integrated license in New Jersey
• Entrance into the Pennsylvania market with the acquistion of Ilera, one of five super license holders
• Focused on creating differentiated products for the global cannabinoid market
• Experienced team with deep ties to global pharmaceutical distribution
• Developing drug preparation premises for non-cannabinoid formulations
• Leverage proximity to Toronto to distribute on behalf of third-party LPs, with same-day delivery capabilities
• Wholesale supply agreements with six Canadian provinces
• Solace Health Network: a place for Canadian cannabis patients to access information and cannabis products

Advancing Research

• Emphasis on developing protectible intellectual property
• Advancing plant genetics and product formulations
• Pharma-grade manufacturing facility

Building Brands

• Developing trusted and recognized brands
• Addressing needs of multiple cannabis business streams
• Defining brands based on deep consumer insights

Promoting Responsibility

• Ensuring highest standard of ethics and corporate integrity
• Advocating responsible use of products
• Exceeding industry and regulatory standards

Optimizing Wellness

• Providing support for medical cannabis use
• Guiding cannabis selection and consumption preferences
• Enhancing the therapeutic application of cannabinoids

Robert Fagan
GMP Securities